Anti-angiogenic drugs, which inhibit the pro-angiogenic effects of vascular endothelial growth factor (VEGF) on its receptor (VEGFR-2), not only normalize tumor blood vessels but also alter the tumor’s immune environment, promoting the infiltration of CD8+ and CD4+ lymphocytes, reversing immune suppression to an inflammatory state (Shrimali et al., 2010; Tian et al., 2017; Ciciola et al., 2020). Here, KDR is linked to neoplasm.